Boston Trust Walden Corp's Investment in Johnson & Johnson

Boston Trust Walden Corp has increased its investment in Johnson & Johnson (NYSE:JNJ) by 6.7% during the third quarter, as reported in their recent filing with the Securities and Exchange Commission (SEC). After acquiring an additional 69,028 shares, the institutional investor now holds 1,093,709 shares of the company's stock. This investment represents approximately 1.2% of Boston Trust Walden Corp's total holdings, making Johnson & Johnson the firm's 10th largest position.

As of the latest filing, the value of Boston Trust Walden Corp's stake in Johnson & Johnson is estimated to be $177,246,000. Other institutional investors are also making changes to their positions in the company. For instance, Innealta Capital LLC entered a new investment in Johnson & Johnson valued at around $27,000 during the second quarter. Mowery & Schoenfeld Wealth Management LLC increased their holdings by 58.7% in the third quarter, bringing their total to 246 shares valued at $40,000 after acquiring 91 additional shares. Similarly, MFA Wealth Advisors LLC and Fairfield Financial Advisors LTD made new investments valued at $43,000 and $46,000, respectively. Fairway Wealth LLC also significantly boosted its stake by 217.1%, adding 228 shares in the second quarter.

Analyst Opinions

Research analysts have been actively reviewing Johnson & Johnson's stock. Daiwa America downgraded the company from a "strong-buy" to a "hold" rating in a report dated July 23rd. Meanwhile, StockNews.com upgraded the stock from "buy" to "strong-buy" on September 14th. The Goldman Sachs Group adjusted its price target for Johnson & Johnson from $160.00 to $155.00, assigning a "neutral" rating in a report from July 19th. Cantor Fitzgerald maintained an "overweight" rating with a price target of $215.00 on October 16th. TD Securities also reduced its price target from $195.00 to $185.00. Overall, six analysts recommend holding the stock, while seven suggest buying and one rates it as a strong buy. MarketBeat.com indicates an average rating of "Moderate Buy" with a target price of $175.93 for the stock.

Insider Activities

In recent insider trading news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson on August 30th at an average price of $165.06, totaling approximately $930,113. Following the transaction, he retains 18,973 shares valued at about $3,131,683. This sale has not significantly altered his ownership percentage, which currently stands at 0.16% of the total stock held by corporate insiders.

Stock Performance Overview

As of Monday, Johnson & Johnson's stock opened at $160.88, with a market capitalization of $387.19 billion. The company has a price-to-earnings (PE) ratio of 10.03, a price-to-earnings-growth (PEG) ratio of 2.90, and a beta of 0.52. Its fifty-day moving average is $163.41, while the 200-day moving average is $155.10. The company’s debt-to-equity ratio is at 0.44, with a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson's stock has experienced a twelve-month low of $143.13 and a high of $168.85.

On October 15th, Johnson & Johnson released its quarterly earnings, reporting an earnings per share (EPS) of $2.42, surpassing analyst expectations of $2.21. The total revenue for the quarter stood at $22.47 billion, which also exceeded projections of $22.17 billion. The company's return on equity was 35.46%, and its net margin was 19.14%. Compared to the previous year, revenue showed a 5.2% increase, although EPS decreased from $2.66 last year. Analysts forecast an average EPS of 9.94 for the current fiscal year.

Dividend Announcement

Johnson & Johnson has also declared its upcoming quarterly dividend, scheduled to be paid on December 10th. Shareholders on record as of November 26th will receive a dividend of $1.24. This dividend results in an annualized payout of $4.96, offering a yield of 3.08%. The dividend payout ratio currently stands at 30.92%.

Company Overview

Johnson & Johnson, along with its subsidiaries, is engaged in the research, development, manufacturing, and sale of various healthcare products around the globe. Its Innovative Medicine segment develops treatments across several therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular health.

Johnson, Investment, Stock